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A B S T R A C T
Purpose: Untreated epilepsy is a major global public health problem with more than 20 million people
not being treated for an easily treatable disease. In part this is due to a lack of trained doctors. There are
many more non-medical health workers than doctors and they could have an important role in diagnosis
and treatment of epilepsy if they had some tools. We have previously described such a tool to distinguish
epileptic episodes from other causes of altered consciousness and here present its validation in three
new populations.
Methods: The tool was presented as a phone app where the answers to 11 questions provided a
probability score which indicated whether episodes might be due to epilepsy or not. It was applied either
by non-medical volunteers, health workers, or inexperienced doctors to 132 patients in three separate
populations in India and Nepal and compared with the ‘‘gold standard’’ diagnosis of a neurologist with
expertise in epilepsy.
Results: There was good agreement between the app score and the neurologists’ diagnoses (weighted
kappa = 75.3%). An app score of 90 or greater had a sensitivity of 88% and a speciﬁcity of 100% for
diagnosing epilepsy. The app was easy to use with little training and took about 5 min to administer.
Conclusion: A tool presented as a phone app can be used by non-medical health workers to identify
episodes as epileptic or not with good accuracy. It needs to be evaluated more widely but has the
potential to play a part in reducing the epilepsy treatment gap.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Untreated epilepsy is a major problem in poorer countries
where about three quarters of people with active epilepsy are not
on treatment [1]. Yet treatment with relatively inexpensive
medication can abolish seizures in about two thirds of such
patients [2]. There are a number or reasons for this treatment gap
one of which is lack of access to doctors of any sort let alone
neurologists [3,4] – in many poorer countries most people live in
the countryside whereas doctors usually live in cities.
Two broad solutions have been suggested to overcome this
treatment gap: the ﬁrst is to delegate functions of diagnosis and
treatment to non-doctors such as nurses, paramedics or village
health workers who are more numerous than doctors and who live* Corresponding author. Present address: Department of Clinical and Experi-
mental Epilepsy, UCL Institute of Neurology, Box 29, 33 Queen Square, London
WC1N 3BG, UK. Tel.: +44 2890448193.
E-mail address: vhp498@gmail.com (V. Patterson).
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights recloser to the people with untreated epilepsy [5,6]. The second is to
educate locally practising doctors and get them to take on a greater
role in epilepsy care with support from specialists [7]. The exact
operational details of these systems of care has not been fully
documented but if either group is to take over a greater role in
epilepsy care they will need some tools to help them. The World
Health Organisation, as part of their Mental Health programme,
have reviewed evidence on the speciﬁc question ‘‘Can convulsive
epilepsy be diagnosed at ﬁrst level care by a non-specialist health care
provider in low and middle income country settings?’’ and concluded
that there was a need for further studies to address this question
[8].
Previously we have described a tool to enable non-doctors to
diagnose episodes of altered consciousness as epileptic or not. This
was developed in Nepal and was based on an analysis of the sort of
questions which comprise routine history taking in this situation
[9]. Questions with the highest likelihood ratios [10] of episodes
being epileptic (E) or not epileptic (NE) were combined sequen-
tially in the tool which then gave a post-test probability score of a
particular episode being E. This mimics the way experiencedserved.
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separating E from NE in a small population of 14 patients. The aim
of the present study is to test its validity in a larger series of
patients from India and Nepal.
2. Methods
2.1. Locations
Patients were studied at three separate locations. These were all
special clinics for people with suspected epilepsy which had been
advertised as widely as possible during the preceding weeks using
local notices, newspapers, local radio and word-of-mouth. Patients
were assessed clinically, in the usual way, by the authors shown in
parentheses. The patients were all new attendances to the authors.
1. An epilepsy clinic on the Lifeline Express Hospital train based at
Raipur India (MS).
2. Epilepsy camps at Dhulikhel Hospital Nepal (VP).
3. Epilepsy camps run by the Nepal Epilepsy Association at three
places in Western Nepal (HR, VP).
2.2. Use of the diagnostic tool
The previously described tool was incorporated into a phone
app to run on AndroidTM phones. This app was developed by
NetProphets Cyberworks Pvt Ltd. Each record consisted of an
identifying clinic number and the 11 questions which had been
deﬁned in the previous study. These are shown in Table 1 with the
available answers.
Using the same algorithm as in the previous study a probability
score for the episode being epileptic was then calculated. The pre-
test probability of having epilepsy from the original study – 0.76 –
was used giving pre-test odds of 3–1 in favour of having epilepsy.
The odds were then multiplied by the likelihood ratio for having
epilepsy of each of the 11 questions inputted sequentially. This
ﬁnal ﬁgure was then converted to a probability score which was
displayed on the phone screen. The records were stored on the
mobile phone and later uploaded to a secure server from which
they could then be downloaded for analysis as a .csv ﬁle. No
patient-identiﬁable information was stored on either the individ-
ual phone or on the server. The record was linked by a study
number to the patient record which avoided duplicate entries.
The tool was used by non-doctors in location 1, by trainee
doctors in location 3, and by a combination of the two in location 2.
The health workers and trainee doctors were trained in using the
phone app by being taken through it once by VP and being given a
three-page set of guidelines. VP was available to answer speciﬁc
questions if required. The average time to use the phone app was
recorded on a sample of the patients at location 1.Table 1
Questions and possible answers used in the phone app.
Questions 
Prior to the episode Gender 
Predisposing factors excluding family history 
During the episode Colour change to red or blue 
Stiffness 
Shaking 
Tongue bitten 
Incontinence of urine 
Head turning to one side 
Eyes 
Able to communicate 
After the episode One-sided weakness At location 1 the tool was used in a separate session either
before or after the clinical consultation. The order was prede-
termined by randomizing study numbers to being assessed either
before or after the clinical consultation. At locations 2 and 3 the
tool was used in the course of the clinical consultation. The trainee
doctor or health worker who entered the data also acted as
translator for VP.
2.3. Clinical assessment
Only patients with episodes of loss of consciousness or
awareness over nine years of age were included. Patients were
seen by a neurologist and their episodes were categorized as
epileptic (E), not epileptic (NE) or uncertain (U). This was done in
the usual way based on a history from the patient and from an
available eyewitness, obtained in person or by phone, followed by
an examination of the patient. The neurologists came to their
conclusion without reference to the phone app score.
2.4. Ethics
The study was approved by the Ethics Committee of the All
India Institute of Medical Sciences.
3. Results
3.1. Patients seen
Details are shown in Table 2.
The ﬁnal diagnoses in those who did not have epilepsy included
a single case of parasomnia with the rest being either non-epileptic
attacks or panic attacks. There were no cases of syncope. At Raipur
it proved impossible to randomize patients into being tested before
or after their clinical consultation as in practice they tended to
disappear after their consultations with the doctor and then the
epilepsy educators. So in practice most app testing was carried out
before the clinical consultation.
3.2. Probability scores
The probability scores as determined by the phone app are
shown in Fig. 1 for each patient in each of the three clinical groups
displayed in ascending order of probability score – E, NE and U. In
general there is near-complete separation between the groups.
Three patients who were clinically uncertain achieved very low
probability scores using the app because there was no eyewitness
available to give an account of the seizure. In future the absence of
an eye-witness combined with a low probability score will
categorize the patient as uncertain. In general, those patients
whom the app categorized as uncertain had less well-describedPossible answers
Male Female
Yes No Not known
Yes No Not known
Yes No Not known
Yes No Not known
Yes No Not known
Yes No Not known
Yes No Not known
Open Closed Not known
Yes No Not known
Yes No Not known
Table 3
App probability scores by decile for each of the three clinical groups – E, U and NE.
Probability score Epilepsy Uncertain Not epilepsy
0–10 0 3 12
11–20 1 0 0
21–30 0 1 1
31–40 0 0 0
41–50 1 1 0
51–60 2 2 0
61–70 4 2 0
71–80 1 0 0
81–90 4 0 0
91–100 97 0 0
Total 110 9 13
Mean 95 35 5
Median 100 43 3
Table 2
The numbers of patients seen at each of the three locations together with their ﬁnal
clinical diagnoses.
Raipur Dhulikhel Western Nepal Total
Epilepsy 62 21 27 110
Not epilepsy 0 11 2 13
Uncertain 0 4 5 9
% with epilepsy 100 58 79 83
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by the app.
The data in shown in tabular form in Table 3 with the mean and
median probability score for each of the three clinical groups.
3.3. Measure of agreement
From Fig. 1 and Table 3, an app probability score of >90 can be
taken to indicate probable epilepsy and an app score <30 probable
non-epilepsy with the remaining 13% being uncertain. This would
have sensitivities and speciﬁcities respectively for epilepsy of 88%
(95% Conﬁdence Interval [CI]: 80.6%, 93.6%) and 100% (95% CI:
75.3%, 100%) and for not epilepsy of 100% and 72%. Table 4 shows
the agreement between the clinician and the app for these three
diagnoses using this paradigm. The weighted kappa scores indicate
a ‘‘good’’ level of agreement.
An alternative paradigm where the app probability score for
epilepsy was >80 would be relevant to 90% of the population and
increase the sensitivity for the diagnosis of epilepsy to 92% without
affecting the other sensitivities and speciﬁcities above.
3.4. Ease of use
Health workers and trainee doctors reported no signiﬁcant
difﬁculties in using the mobile phone app. Minimal input from VP
was required. The average time to complete the app questions was
5 min.
4. Discussion
This phone app is effective in diagnosing epileptic and non-
epileptic seizures in the two Nepalese and one Indian populations
in which it was studied. This conﬁrms the promise shown in its
development and early validation phases [9]. It clearly separates
the three different clinical diagnoses – epilepsy, not epilepsy and
uncertain. Even with very conservative limits for diagnosis, it is
applicable to over 85% of presenting patients, its sensitivity and
speciﬁcity for both epileptic and non-epileptic attacks are high andFig. 1. Probability scores for 132 individual patients by type of clinical diagnosis
displayed in ascending order of probability score.it compares well with clinical diagnosis when measured by the
kappa statistic. In practice it was easy for non-doctors to use with
very little instruction and took only about 5 min to administer.
This validation study was carried out in three different ‘‘real-
life’’ settings in over 100 patients and using a mixture of volunteers,
health workers and inexperienced doctors to administer the app.
Three different neurologists provided the ‘‘gold standard’’ clinical
diagnosis compared to single neurologist in the early validation
study. The three settings provided different percentages of patients
who had epilepsy – 100% in Raipur, 56% at Dhulikhel and 79% in
Western Nepal. There are many possible explanations for this
difference including variations in how the clinic announcements
were made and interpreted in local languages, and how non-
epilepsy patients were recorded. One part of the algorithm used by
the app is pre-test probability of 0.76 for someone having epilepsy,
this ﬁgure being derived from a study in Nepal. Whether this is
important in populations where the pre-test probability may be
higher or lower should be evident from studies in different
populations such as the present one. If pre-test probability is indeed
100% then of course there is no need for an app.
Presenting the tool as a phone app has a number of distinct
advantages: ﬁrst people are more likely to have a mobile phone
than a laptop or a programmable calculator. Second it is easier to
enter the data than, for example, using paper. Third it is easy to
aggregate and analyze results by uploading the data to a webserver
when back in an area where there is a wireless Internet connection.
Fourth it is easy to update and improve the tool; for example in this
study we showed that if there is no eye witness available then
diagnoses of non-epileptic episodes were made by the app when
the correct clinical diagnosis was uncertain; it is easy to provide an
update to the app which includes a rule that, if no eye witness is
available and the probability score is less than 30, then the episode
should be regarded as uncertain. Indeed this has already been
done. Also the score above which epilepsy was regarded as
probable was set at 90 prior to the study. The results show that the
sensitivity could be increased by recalibrating this to 80 without
any loss of speciﬁcity.Table 4
Agreement between app and clinician diagnoses in 132 patients using an app score
of >90 as epilepsy and one <30 as not epilepsy.
Diagnosis by
phone app
Diagnosis by neurologist Total
No epilepsy Uncertain Epilepsy
No epilepsy 13 4 1 18
Uncertain 0 5 12 17
Epilepsy 0 0 97 97
Total 13 9 110 132
Weighted kappa = 75.3% (95% CI: 60.9%, 89.7%).
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carefully-controlled clinic setting so it was not possible to
eliminate a number of sources of potential bias such as whether
patients already on treatment for epilepsy might react differently
to untreated patients and whether the order of testing before or
after the clinical consultation might be relevant and whether
subtle cues from the translator might have altered the outcome.
Also it could be argued that not all health workers will have
smartphones. This may well be the case at present but statistics on
mobile phone usage from resource-poor countries suggests an
exponential growth of smartphone usage [11] so it is unlikely to be
the case in a few years time.
No diagnostic tool is ever going to be 100% accurate in
diagnosing an episode of altered consciousness as epileptic. The
levels of agreement between the tool and the neurologists in this
study are however very much better than published inter-
physician agreement from the UK in the 1990s where misdiagnosis
rates of 20–30% were found in those attending a specialist epilepsy
service [12]. Details of the misdiagnosis rate in primary care in
poorer countries are more difﬁcult to come by.
Another potential use of this tool is in screening populations for
epilepsy in door-to-door surveys. The present methods of doing
this involve screening questionnaires such as those reviewed by
the World Health Organisation (WHO) [8]. The sensitivity and
speciﬁcity of this tool is as good as any of those described and
compares well with the sensitivity of 72% and speciﬁcity of 100% in
a study from Asia [13]. Again the availability of a tool as a phone
app makes data collection and interrogation much simpler.
However this app has a narrow footprint, having been tested only
in areas of Nepal and India and needs to be tested in other poorer
countries. The app is also unlikely to be reliable in epilepsy
populations in richer countries which will have very different
clinical characteristics. This is the case in a tertiary referral centre
in Scotland (Dr. Aline Russell, personal communication).
5. Conclusion
This tool is only one piece of the jigsaw in delivering treatment
to the 20 million people with epilepsy who are presently
untreated. And diagnosing an episode as epileptic is only one
step in determining whether treatment is required and if so which
treatment. The app [14] now needs to be used and tested in wider
areas to see if it can fulﬁl its early promise and other medical pieces
of the jigsaw, such as frequency and provocation of episodes, now
need to be addressed in a similar fashion. Untreated epilepsy is
mostly a public health problem but it has some important medical
aspects. When these can be devolved safely to non-doctors then
dealing with the public health problem will be much easier.Conﬂict of interest statement
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